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Background: The purpose of this observational study was to test the diagnostic performance 
of the Elecsys® troponin T high-sensitive system combined with copeptin measurement for 
early exclusion of acute myocardial infarction (MI) in clinical practice.
Methods: Troponin T high-sensitive (diagnostic cutoff: ,14 pg/mL) and copeptin (diagnostic 
cutoff: ,14 pmol/L) levels were determined at admission in addition to other routine laboratory 
parameters in patients with suspected acute MI presenting to the emergency department of a 
general hospital over a period of five months.
Results: Data from 142 consecutive patients (mean age 71.2 ± 13.5 years, 76 men) were 
analyzed. Final diagnoses were acute MI in 13 patients (nine ST elevation MI, four non-ST 
elevation MI, 9.2%) unstable angina pectoris in three (2.1%), cardiac symptoms not primar-
ily associated with myocardial ischemia in 79 (55.6%), and noncardiac disease in 47 patients 
(33.1%). The patients with acute MI were younger and had higher troponin T high-sensitive and 
copeptin values than patients without acute MI. Seventeen patients had very high copeptin values 
(.150 pmol/L), one of whom had a level of .700 pmol/L and died of pulmonary embolism. 
A troponin T high-sensitive level of ,14 pg/mL in combination with copeptin ,14 pmol/L at 
initial presentation ruled out acute MI in 45 of the 142 patients (31.7%), each with a sensitivity 
and negative predictive value of 100%.
Conclusion: According to this early experience, a single determination of troponin T high-
sensitive and copeptin may enable early and accurate exclusion of acute MI in one third of 
patients, even in an emergency department of a general hospital.
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Introduction
According to a World Health Organization report dated January 2011,1 an estimated 
7.2 million deaths per year worldwide are due to acute myocardial infarction (MI) 
or other ischemic disorders of the heart. Rapid detection and diagnostic accuracy is 
crucial to ensure early effective treatment of this life-threatening disease, which is 
associated with myocardial cell death due to ischemia, and most often a consequence 
of acute thrombus formation. Thus, both reliable confirmation of the diagnosis and 
accurate exclusion of acute MI is of great importance for establishing a rational 
management system for patients with suspected acute MI in the emergency depart-
ment which, in turn, would result in optimal utilization of available resources. 
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the release of troponin. Serum troponin, a very sensitive 
marker, has been determined using the assays for conven-
tional troponin T and I for several years now. However, 
recently, a new highly sensitive assay for detecting serum 
troponin has been developed. The introduction of this 
new assay offers the opportunity for improved diagnostic 
accuracy and early detection of acute MI.2 Although it is 
capable of detecting myocardial necrosis earlier than con-
ventional troponin assay,2 there remains a troponin-blind 
interval after onset of chest pain due to the delayed release 
of troponin following a cardiac injury.3 Therefore, there is 
a need for a biomarker that is released immediately in the 
event of endogenous stress, such as onset of chest pain due 
to acute myocardial ischemia.
In this setting, one of the major hypothalamic stress 
  hormones, arginine vasopressin, comes into play.   However, 
due to its unstable nature and rapid clearance from 
plasma, measurements of arginine vasopressin are rarely 
reproducible.4–6 Copeptin, a glycosylated peptide precursor 
of arginine vasopressin, is more stable and easier to measure. 
Its levels adequately represent the production of arginine 
  vasopressin.7 In recent years, the prognostic accuracy of 
copeptin as a stress hormone has been demonstrated in 
sepsis,8,9 pneumonia and lower respiratory tract infections,10,11 
heart disease,12–14 and stroke.15,16 According to the pathophysi-
ological findings,17,18 the arginine vasopressin system can also 
be counted amongst the neurohumoral pathways, in addition 
to the renin-  angiotensin-aldosterone and sympathetic nervous 
systems. If the organism is exposed to endogenous stress, 
such as acute MI, the arginine vasopressin system is activated 
and copeptin is released. In patients with acute MI, copeptin 
levels are highest within 3–4 hours of onset of chest pain,19,20 
peak on day 1, decrease slightly on day 2, and then reach a 
plateau 3–5 days after acute MI.13
Rapid and accurate exclusion of acute MI might be pos-
sible in up to two thirds of patients with typical chest pain 
by the combined determination of conventional troponin 
T and copeptin, a new biomarker, according to two recent 
studies.19,20 The aim of the present observational study was 
to assess whether combined determination using the new 
Elecsys® troponin T high-sensitive system,21,22 which meets 
the current European Society of Cardiology/American 
College of Cardiology criteria for detection of myocardial 
necrosis, and copeptin, which provides additional diagnos-
tic information compared with determination of troponin T 
high-sensitive alone, is useful for the evaluation of patients 
with symptoms suggestive of acute MI in an emergency 
department of a general hospital.
Methods
Patients
A total of 150 consecutive patients with chest pain or other 
symptoms suggestive of acute MI presenting to the emer-
gency department of the Saale-Unstrut Hospital Naumburg 
(Germany) between January and June 2010, were initially 
recruited for the study. Patients with end-stage renal disease 
undergoing dialysis were excluded. All patients included in 
the study gave their written informed consent.
Routine examinations at admission
Routine clinical examinations, including standard 12-lead 
electrocardiography (ECG), blood pressure measurement, 
pulse oximetry monitoring, and chest radiography were 
performed in all patients. Benchmark blood parameters and 
specific myocardial markers, such as creatine kinase MB 
fraction, and troponin T high-sensitive were determined at 
presentation, then at 6–9 hours24 after admission, accord-
ing to the clinical situation. Additionally, for the first time, 
the new biomarker copeptin was measured at presentation. 
Diagnostic procedures and treatment in all patients were 
performed according to a standardized inhouse protocol. In 
unclear cases, a consensus between the attending physician 
and consultant colleagues was reached.
Definition of acute MI
According to the current recommendations,23,25 a diagno-
sis of acute MI is confirmed when myocardial necrosis in 
combination with typical clinical symptoms of ischemia 
and ECG changes, such as new ST-T wave changes, new 
left bundle branch block, or development of new pathologic 
Q waves,25 can be accurately detected. In the present study, 
the diagnosis of acute MI was based on the consensus defi-
nition from 2007,25 requiring the detection of myocardial 
necrosis with a troponin T concentration from at least one 
measurement exceeding the 99th percentile with a coef-
ficient of variation of ,10% and dynamic changes, with 
a typical increase and/or decrease of the serum level.25,26 
In order to fulfill these strict criteria, a high-sensitivity 
assay for troponin T (Elecsys® troponin T high-sensitive; 
cobas® e 601, Roche Diagnostics, Mannheim, Germany)21,22 
as well as a   fourth-generation27 troponin T assay (Roche 
Diagnostics) were used.
Laboratory investigations
All myocardial markers, including creatine kinase and its 
MB fraction, were analyzed according to the manufacturer`s 
instructions. A troponin T high-sensitive value of ,14 pg/mL Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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was defined as the cutoff level, representing the 99th   percentile 
of the upper limit in a healthy reference population.22
Blood samples for the measurement of the biomarker 
copeptin (BRAHMS AG, Henningsdorf, Germany), were stored 
in tubes with potassium ethylenediamine tetra-acetic acid, 
centrifuged, frozen at −80°C, and then analyzed as described 
previously.7 For copeptin, a cutoff value of ,14 pmol/L was 
specified for rapid exclusion of acute MI, as recommended by the 
manufacturer and used by Reichlin et al19 in a recent study.
ecg analysis
The 12-lead ECGs at admission were analyzed by the 
attending physician as well as an internal medicine spe-
cialist or cardiologist, neither of whom were aware of the 
patient’s clinical and laboratory parameters. With respect to 
the changes indicating acute MI, all ECGs were analyzed on 
the basis of the current recommendations.23,25
statistical analysis
Categorical data are presented as numbers or relative frequen-
cies and continuous data as means ± standard deviation (SD) 
or medians with interquartile range (IQR). For comparison 
of continuous variables between groups and for categorical 
variables, the analysis of variance test and Fisher’s Exact 
test were employed, respectively. The Spearman rank 
correlation coefficient was used to assess the association 
between troponin T high-sensitive and copeptin. In order 
to examine the significance of the combination of troponin 
T high-sensitive and copeptin for the diagnosis of acute 
MI irrespective of other variables, the logistic regression 
was applied. A P value ,0.05 was accepted as statistically 
  significant. Sensitivity, specificity, positive predictive values, 
and negative predictive values for troponin T high-sensitive, 
copeptin, and the combination of both biomarkers were also 
calculated using the marker-specific cutoffs of ,14 pg/mL 
or ,14 pmol/L, respectively, as described above.
Results
Baseline patient characteristics
Of the 150 patients initially included in the study, eight were 
excluded due either to missing laboratory values for troponin T 
high-sensitive or copeptin levels, so that data from 142 patients 
(mean age 71.2 ± 13.5 years, 76 men) were analyzed. Acute MI 
(ST elevation MI, n = 9; non-ST elevation MI, n = 4) was diag-
nosed in 9.2% (13/142) of patients. The remaining 129 patients 
were diagnosed as follows: unstable angina in 2.1% (3/142), 
cardiac disease not primarily associated with coronary artery 
disease (including four patients with pulmonary embolism) in 
55.6% (79/142), and noncardiac disease in 33.1% (47/142). 
Baseline clinical characteristics are summarized in Table 1.
Highly sensitive troponin T measurements
In all patients, the median troponin T high-sensitive level 
was 14 (IQR 6.3–41.75) pg/mL. For the intra-assay coef-
ficient of variation, a value of 3.4% was calculated. At initial 
  presentation, 49% (70/142) of the patients met the cutoff level 
of troponin T high-sensitive of ,14 pg/mL. Only one (7.7%) of 
the 13 patients with acute MI had a troponin T high-sensitive 
concentration of ,14 pg/mL at admission. This patient came to 
the emergency department within four hours of onset of chest 
pain. In contrast, 69 of the 129 patients (53.5%) without acute 
MI showed a troponin T high-sensitive level of ,14 pg/mL.
Patients with acute MI showed higher values (P , 0.0001) 
for troponin T high-sensitive (median 135.0 pg/mL, IQR 
41.9–440.0 pg/mL) than those with unstable angina pectoris 
(median 3.0 pg/mL, IQR 3.0–5.6 pg/mL), other cardiac but 
not primarily ischemia-related disease (median 22.0 pg/mL, 
IQR 10.1–52.8 pg/mL), or noncardiac disease (median 
7.0 pg/mL, IQR 3.8–12.5 pg/mL, Figure 1).
copeptin measurements
The median copeptin level in the study population was 
15.70 pmol/L (IQR 7.28–62.90 pmol/L). The intra-assay coef-
ficient of variation showed a value of 5.9%. In 45.8% (n = 65) 
of the 142 patients, the cutoff level of ,14 pmol/L was found 
at admission. Of the patients diagnosed with acute MI, 30.8% 
(4/13) had a copeptin level of ,14 pmol/L. Two of the four 
patients with ST elevation MI presented 5–8 days after initial 
onset of chest pain, one patient had a prolonged reinfarction 
after acute coronary intervention one week earlier, and one 
patient had non-ST elevation MI and sustained angina changing 
between resolution and recurrence for two days after onset of 
chest pain. The copeptin level was ,14 pmol/L in 47.3% of 
patients (61/129) without acute MI. Values for copeptin in acute 
MI patients (median 30.4 pmol/L, IQR 5.0–139.0 pmol/L) dif-
fered significantly (P , 0.05) from those in patients with unsta-
ble angina pectoris (median 9.7 pmol/L, IQR 8.6–10.6 pmol/L), 
other nonischemic cardiac disease (median 19.6 pmol/L, IQR 
9.2–72.8 pmol/L), or noncardiac disease (median 8.9 pmol/L, 
IQR 5.4–23.2 pmol/L, Figure 1).
Association between highly sensitive 
troponin T and copeptin
There was a positive correlation between troponin T high-
sensitive and copeptin levels at the time of initial presentation 
(r = 0.41; P , 0.001).Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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combination of both biomarkers for early 
exclusion of acute Mi
A value of ,14 pg/mL for troponin T high-sensitive could 
be used for rapid exclusion of acute MI with a sensitivity 
of 92.3%, specificity of 53.5%, positive predictive value of 
16.7%, and negative predictive value of 98.6%. The cor-
responding values for the biomarker copeptin were 69.2%, 
47.3%,11.7%, and 93.9%, respectively. A troponin T high-
sensitive level of ,14 pg/mL in combination with a copeptin 
value of ,14 pmol/L at initial presentation excluded acute MI 
with a sensitivity of 100%, specificity of 34.9%, positive pre-
dictive value of 13.4%, and negative predictive value of 100%, 
indicating that this combination has an even higher diagnostic 
accuracy than that of either troponin T high-sensitive or copep-
tin alone. In 45 (31.7%) of the 142 patients, acute MI could 
be accurately excluded by a single determination of troponin 
T high-sensitive and copeptin (Figure 2). After adjusting for 
other baseline variables, both troponin T high-sensitive alone 
and the combination of troponin T high-sensitive and copeptin 
remained very significant diagnostic parameters for acute MI 
(P , 0.001 for troponin T high-sensitive alone and for the 
combination of troponin T high-sensitive and copeptin), while 
statistical significance was not reached for copeptin alone.
Patients with very high copeptin levels
Seventeen patients (12%) had copeptin levels of .150 pmol/L. 
Of these, only three patients were diagnosed with acute MI. 
Among the remaining 14 patients, three suffered acute   
pulmonary embolism, of whom one with a copeptin level of 
730 pmol/L died whilst in hospital. The remaining 11 patients 
were diagnosed as follows: atrial tachycardia (n = 1); decom-
pensated heart failure (n = 4); left-sided pneumonia, urinary 
tract infection, hypotension, and dehydration (n = 1); severe 
bilateral pneumonia, hypotension, and dehydration (n = 1); 
angina pectoris with profound hyperglycemia (n = 1); chest 
pain and faint of unknown origin (n = 1); and two patients 
had been resuscitated just before admission to hospital.
Limitations
The main limitation of this observational study was the small 
number of enrolled patients and therefore a low event rate. 
Another limitation is the fact that the study patients were 
recruited on a nonselected basis in an emergency department 
of a general hospital and not in a specialized chest pain unit 
where patient selection would occur.
Discussion
We have demonstrated for the first time that combined appli-
cation of troponin T high-sensitive (using the 99th percentile 
as a diagnostic cutoff with a 10% coefficient of variation23,25) 
and copeptin may enable early accurate exclusion of acute 
MI. In the present observational study, acute MI could be 
ruled out with a negative predictive value of 100% in one 
third of patients who presented with symptoms suggestive of 
Table 1 clinical baseline characteristics of patients
Clinical characteristics All patients (n = 142) AMI (n = 13) Non-AMI (n = 129) P value
Age (years) 71.2 ± 13.5 64.5 ± 11.2 71.8 ± 13.6 0.06
Men (%) 53.5 (76) 84.6 (11) 50.4 (65) 0.02
Cardiovascular risk factors
Hypertension (%) 73.9 (105) 92.3 (12) 72.0 (93) 0.18
Diabetes mellitus (%) 28.9 (41) 46.2 (6) 27.1 (35) 0.2
Hyperlipidemia (%) 16.9 (24) 38.5 (5) 14.7 (19) 0.04
current smokers (%) 7.7 (11) 30.8 (4) 5.4 (7) 0.01
Overweight (%) 9.2 (13) 15.4 (2) 8.5 (11) 0.34
History
Known cAD (%) 27.5 (39) 30.8 (4) 27.1 (35) 0.75
Prior Pci (%) 10.6 (15) 30.8 (4) 8.5 (11) 0.03
Prior AMi (%) 15.5 (20) 23.1 (3) 13.2 (17) 0.4
Prior cABg (%) 5.6 (8) 0 (0) 6.2 (8) 1
Prior stroke/TiA (%) 7.0 (10) 23.1 (3) 5.4 (7) 0.05
Valvular heart disease 9.2 (13) 0 (0) 10.1 (13) 0.61
ECG findings at admission
Pacemaker ecg (%) 4.2 (6) 0 (0) 4.7 (6) 1
LBBB (%) 4.4 (6) 0 (0) 4.9 (6) 1
sT segment depression (%) 29.2 (38)a 23.1 (3) 29.9 (35)b 0.75
sT segment elevation (%) 6.9 (9)a 69.2 (9) 0 (0)b ,0.0001
Notes: Data are given as mean ± sD, or relative frequencies (n) aof 130 patients; bof 117 patients.
Abbreviations: AMi, acute myocardial infarction; cABg, coronary artery bypass grafting; cAD, coronary artery disease; ecg, electrocardiogram; LBBB, left bundle branch 
block; Pci, percutaneous coronary intervention; sD, standard deviation; TiA, transient ischemic attack.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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acute MI to the emergency department of a general hospital. 
Compared with troponin T high-sensitive alone, additional 
determination of copeptin at initial presentation led to a small 
diagnostic improvement in exclusion of acute MI in only one 
third of the patients. This finding is in line with data from 
Keller et al20 who described a negative predictive value of up 
to 99% using the combination of a more sensitive troponin T 
(with the 99th percentile as a cutoff with 10% coefficient of 
variation) and copeptin for ruling out acute MI.
In comparison with two recent studies19,20 reporting exclu-
sion of acute MI using this algorithm in two thirds of patients 
with angina, the discrepancy in the present investigation is 
likely due to the small study population and the low number 
of events. Furthermore, our patients were recruited from 
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Figure 1 Box plots (median, interquartile range) of TropT hs (A) and copeptin (B) in the four patient groups with AMi (n = 13), UAP (n = 3), cardiac disease, but not primarily 
due to myocardial ischemia (n = 79), or noncardiac diseases (n = 47) at the time point of presentation to the emergency department.
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the emergency department of a general hospital situated in 
a rural region, and hence did not have the same risk of acute 
MI as did the patients in the two abovementioned studies 
which recruited patients from the emergency departments 
of university or urban hospitals.19,20
The lack of correlation between ischemic symptoms and 
objectively assessable myocardial necrosis in the one acute MI 
patient with a troponin T high-sensitive value of ,14 pg/mL 
presenting within four hours of onset of chest pain to the 
emergency department corresponds with the well known 
fact that early presenters often have a delay in a detectable 
increase in troponin concentration.28 In contrast, copeptin 
levels of ,14 pmol/L in three acute MI patients presenting 
on days 2–8 after onset of chest pain and in one patient with a 
prolonged reinfarction after coronary intervention for acute MI 
one week prior to the recurrent ischemic event are in line with 
observations from a previous study13 describing an increase in 
the copeptin level peaking on day 1 after onset of chest pain, 
followed by a decrease on day 2, after which the copeptin 
levels remained constant at days 3–5. From the pathophysi-
ological point of view, falling copeptin levels just one day 
after the myocardial ischemic event may indicate adaptation to 
neurohumoral stress via activation of the arginine vasopressin 
system17,18 following acute myocardial ischemia.13
In both situations, the complementary biomarker was 
elevated, indicating that, especially in early and late pre-
senters with acute MI, the combined application of the two 
biomarkers, troponin T high-sensitive and copeptin, may 
contribute to diagnostic accuracy and enable an estimation 
of the time interval elapsed since onset of chest pain and 
presentation to the emergency department.
With regard to the 17 patients with very high copeptin 
values of .150 pmol/L, the results of our study are in accor-
dance with the known fact that copeptin is an endogenous 
stress hormone reaching markedly elevated levels in criti-
cally ill patients.29,30 In the present study, this phenomenon 
could be observed for cardiac diseases such as acute MI, 
decompensated heart failure, and atrial tachycardia, as well 
as in other serious diseases, including acute pulmonary 
embolism, febrile pneumonia, and acute illnesses associ-
ated with depression of the circulation. Taking into account 
that one patient with acute pulmonary embolism showing a 
copeptin level of .700 pmol/L at initial presentation died 
during the inhospital stay, our data confirm that a very high 
copeptin value may also reflect critical disease states other 
than acute MI,29 and may be considered a significant predictor 
of outcome in certain cases, such as in patients with acute 
pulmonary embolism.
On the basis of this first clinical experience, it is not pos-
sible to make any definitive statements with regard to the diag-
nostic significance of the combined assessment of troponin T 
high-sensitive and copeptin for exclusion of acute MI. Further 
prospective, multicenter studies with serial measurements of 
both biomarkers and longer follow-up of patients are needed 
to confirm the diagnostic role of the combination of these two 
new biomarkers in patients with suspected acute MI.
Conclusion
Early measurement of the combination of troponin T high-
sensitive and copeptin may revolutionize the diagnostic 
accuracy and therapeutic decision-making in patients with 
symptoms suggestive of acute MI. A single combined deter-
mination of troponin T high-sensitive and copeptin enables 
early exclusion of acute MI in one third of patients with a 
negative predictive value of 100%, even in an emergency 
department of a general hospital. Additionally, it allows esti-
mation of the time interval between onset of chest pain and 
presentation with acute MI to the emergency department. This 
algorithm has the potential to contribute to rational allocation 
of available resources for patients presenting with chest pain 
to emergency departments.
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